secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001213900-24-085641
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed
--------------------------------------------------------------------------------

- George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.
- Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.
- Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).
- No family relationships or transactions requiring disclosure under Item 404(a) exist.
- Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/ea0216701-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-085641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer